In addition, the combination treatment also affected the anti-tumor immune response in other organs, as observed by a rise of the CD8+ and CD4+ T cells in the spleen, increasing the secretion of pro-inflammatory cytokine IL-12, and decreasing the secretion of pro-tumor inflammatory factor IL-6 (Fig. 5). The gene discussed is CD8A; the disease is neoplasm.